Products - Inflammatory bowel disease | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 44 products

Date | Title

Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2024
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 March 2024
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 October 2023
Upadacitinib for previously treated moderately to severely active Crohn’s disease (TA905)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 May 2023
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 January 2023
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 October 2022
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) (TA826)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 September 2022
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
20 September 2022
Published:
23 March 2011
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 June 2022
PredictSURE IBD and IBDX to guide treatment of Crohn’s disease (DG45)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
23 February 2022
Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 June 2020
Crohn’s disease: management (NG129)
Product type:
Guidance
Programme:
NICE guideline
Published:
3 May 2019
Ulcerative colitis: management (NG130)
Product type:
Guidance
Programme:
NICE guideline
Published:
3 May 2019
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease (TA556)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2019
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 November 2018
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment (TA456)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2017
Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
17 February 2016
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2015
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2015
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
2 October 2013
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 May 2010
Extracorporeal photopheresis for Crohn's disease (IPG288)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 February 2009
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 December 2008
Computed tomographic colonography (virtual colonoscopy) (IPG129)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 June 2005
Leukapheresis for inflammatory bowel disease (IPG126)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 June 2005
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
10 January 2023
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
12 July 2022
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis (ES35)
Product type:
Advice
Programme:
Evidence summary
Published:
24 February 2021
Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 December 2017
RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
20 June 2017
Inflammatory bowel disease (QS81)
Product type:
Quality standard
Published:
26 February 2015
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 July 2025
Guselkumab for treating moderately to severely active ulcerative colitis ID6237
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 July 2025
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TSID10755]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apraglutide for treating short bowel syndrome [ID6533]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC